Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Portrait de Lynn Seely
Leeftijd : 61
Vermogen : 41 733 470 USD
Belangrijkste bedrijven : Blueprint Medicines Corporation - Lyell Immunopharma, Inc.
Overzicht 
Dr. Lynn Seely, MD, is an Independent Director at Lyell Immunopharma, Inc. and an Independent Director at Blueprint Medicines Corp.

She is on the Board of Directors at Lyell Immunopharma, Inc. and Blueprint Medicines Corp. Dr. Seely was previously employed as a Chief Executive Officer & Director by Myovant Sciences Ltd., a Chief Executive Officer by Myovant Sciences, Inc., a Chief Medical Officer by Orion Acquisition Corp. II, a Chief Medical Officer & Senior Vice President by Medivation LLC (California), a Vice President-Clinical Development by Anesiva, Inc., a Vice President-Clinical Development by Corgentech, Inc., a Vice President-Clinical Development by Cytyc Health Corp., a Vice President-Clinical Development by Pro-Duct Health, Inc., an Associate Director-Clinical Development by Chiron Corp., a Faculty Member by University of California San Diego, and a Chief Resident-Internal Medicine by Yale School of Medicine.

She also served on the board at Roivant Sciences GmbH.

She received her undergraduate degree from the University of Oklahoma and a doctorate degree from the University of Oklahoma College of Medicine.


Posities en verantwoordelijkheden van Lynn Seely 
NaamTitel Van
Blueprint Medicines Corporation
(Biotechnologie & Medisch Onderzoek)
Independent Director 2016
Lyell Immunopharma, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2021


Belangnemingen van Lynn Seely 
NaamAandelen%Totale waarde
Myovant Sciences Ltd. (MYOV)
(Biotechnologie & Medisch Onderzoek)
1 692 3331,84%41 191 385 USD
Blueprint Medicines Corporation (BPMC)
(Biotechnologie & Medisch Onderzoek)
5 8120,0099%542 085 USD
Lyell Immunopharma, Inc. (LYEL)
(Biotechnologie & Medisch Onderzoek)
00,0000%0 USD


Lynn SeelyPersoonlijk netwerk 
Meest gelezen nieuws 
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
Lynn Seely Verbindingen